Hill March 8, 2024
Novo Nordisk’s weight loss medication Wegovy received approval on Friday for reducing the risk of cardiovascular death, heart attack and stroke in patients with cardiovascular disease and obesity.
The Food and Drug Administration (FDA) cited the results of a multi-national study that involved 17,600 participants who either received Wegovy or a placebo. The results found that the risk of a major adverse cardiovascular events was statistically reduced to 20 percent among patients who received the drug.
These benefits were observed among participants regardless of “baseline age, sex, race, ethnicity, body mass index (BMI) and level of renal function impairment.” Novo Nordisk noted the mechanism through which this reduction occurs has not yet been established.
“Wegovy is now the first weight...
Today's Sponsors
Today's Sponsor